

Mitroflow® vs Perimount® international clinical evaluation

Submission date 23/11/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/01/2008	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 09/05/2016	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Malcolm Dalrymple-Hay

Contact details
Department of Cardiothoracic Surgery
Plymouth Hospitals NHS Trust
Plymouth
United Kingdom
PL6 8DH
+44 1392 262175
malcolm@dalrymple-hay.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
V10603

Study information

Scientific Title

Mitroflow® vs Perimount® international clinical evaluation

Acronym

FLORENCE

Study objectives

Comparison of haemodynamic data (mitroflow® vs perimount® valves)

Ethics approval required

Old ethics approval format

Ethics approval(s)

To be submitted as of 23 November 2007

Study design

Prospective randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Aortic stenosis

Interventions

Aortic valve replacement (Mitroflow® vs Perimount® valves)

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

The following haemodynamic data will be assessed at one and six months post implantation:

1. Effective orifice area
2. Mean pressure gradient
3. Peak pressure gradient
4. Degree LV remodelling

Secondary outcome measures

Morbidity and mortality. Duration of follow-up: Six months post implantation

Overall study start date

01/01/2008

Completion date

30/06/2009

Eligibility

Key inclusion criteria

Patients undergoing Aortic Valve Replacement (AVR) with annulus less than 25 cm

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

150

Key exclusion criteria

1. Poor left ventricular function
2. Redo-aortic valve replacement
3. Other associated disorders
4. Aged greater than 70 years

Date of first enrolment

01/01/2008

Date of final enrolment

30/06/2009

Locations

Countries of recruitment

Belgium

England

Italy

Switzerland

United Kingdom

Study participating centre

Department of Cardiothoracic Surgery

Plymouth

United Kingdom

PL6 8DH

Sponsor information

Organisation

Sorin Biomedica Cardio S.R.L (Italy)

Sponsor details

Via Crescentino sn

Sallugia (VC)

Italy

13040

+39 75 5784281

direzione.medica@sorin.com

Sponsor type

Industry

Website

<http://www.sorin.com/>

ROR

<https://ror.org/01ys7qn31>

Funder(s)

Funder type

Industry

Funder Name

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration